Highlights
- •A restricted panel of 44 genes discerns BM1/BM2 subtypes of BRAF mut mCRC.
- •AXIN2 expression distinguishes LI versus LD Wnt pathway activation of BRAF mut mCRC.
- •No prognostic impact was shown for both BM1/BM2 and LI/LD subtypes.
- •No predictive effect of both BM1/BM2 and LI/LD subtypes was shown for FOLFOXIRI/bev.
- •ECOG-PS >0 and left-sidedness seem associated with no benefit from FOLFOXIRI/bev.
Abstract
Background
Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit
from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study.
Patients and methods
Clinical characteristics and gene expression signatures of patients with BRAF-mutant mCRC enrolled in the TRIBE2 study were evaluated with the aim of understanding that patients
may derive benefit from the intensification of the upfront chemotherapy.
Results
Of 46 BRAF-mutant tumour samples analysed, 24 (52%) and 22 (48%) were classified as
BM1 and BM2, respectively, and 27 (59%) and 19 (41%) were assigned to ligand-independent
(LI) and ligand-dependent (LD) Wnt pathway subgroups, respectively. No prognostic
impact was shown for both BM1/BM2 and LI/LD subtypes. No interaction was evident between
BM1/BM2 or LI/LD signatures and the benefit provided by FOLFOXIRI/bevacizumab. Significant
interaction effect was evident in terms of progression-free survival between treatment
arm and primary tumour sidedness (P = 0.05) and Eastern Cooperative Oncology Group performance status (ECOG-PS; P < 0.001).
Conclusions
Gene expression analysis failed to identify patients with BRAF-mutant mCRC candidate to upfront FOLFOXIRI/bevacizumab. ECOG-PS >0 and left-sidedness seem associated
with no benefit from the intensified treatment.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Mutations of the BRAF gene in human cancer.Nature. 2002; 417: 949-954https://doi.org/10.1038/nature00766
- KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27: 5931-5937https://doi.org/10.1200/JCO.2009.22.4295
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.Cancer. 2011; 117: 4623-4632https://doi.org/10.1002/cncr.26086
- Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.Clin Colorectal Canc. 2014; 13: 164-171https://doi.org/10.1016/j.clcc.2014.06.001
- Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.Ann Oncol Off J Eur Soc Med Oncol. 2017; 28: 562-568https://doi.org/10.1093/annonc/mdw645
- LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer.Ann Oncol. 2020; 31: S242-S243https://doi.org/10.1016/j.annonc.2020.04.080
- An open-label, multicenter, randomized phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic braf v600e-mutant colorectal cancer.Clinicaltrials.gov, 2021
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Ann Oncol. 2016; 27: 1386-1422https://doi.org/10.1093/annonc/mdw235
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.Lancet Oncol. 2010; 11: 845-852https://doi.org/10.1016/S1470-2045(10)70175-3
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.Eur J Canc. 2014; 50 (Oxf Engl 1990): 57-63https://doi.org/10.1016/j.ejca.2013.08.024
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.Lancet Oncol. 2015; 16: 1306-1315https://doi.org/10.1016/S1470-2045(15)00122-9
- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.Lancet Oncol. 2020; 21: 497-507https://doi.org/10.1016/S1470-2045(19)30862-9
- Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer.J Clin Oncol Off J Am Soc Clin Oncol. 2020; (JCO2001225)https://doi.org/10.1200/JCO.20.01225
- BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis.Colorectal Dis Off J Assoc Coloproctology G B Irel. 2013; 15: e711-e718https://doi.org/10.1111/codi.12427
- A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the “BRAF BeCool” study.Eur J Canc. 2019; 118 (Oxf Engl 1990): 121-130https://doi.org/10.1016/j.ejca.2019.06.008
- CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.Br J Canc. 2019; 121: 593-599https://doi.org/10.1038/s41416-019-0560-0
- Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.Clin Canc Res Off J Am Assoc Canc Res. 2014; 20: 5322-5330https://doi.org/10.1158/1078-0432.CCR-14-0332
- BRAF V600E mutant colorectal cancer subtypes based on gene expression.Clin Canc Res Off J Am Assoc Canc Res. 2017; 23: 104-115https://doi.org/10.1158/1078-0432.CCR-16-0140
- BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer.Clin Canc Res Off J Am Assoc Canc Res. 2020; 26: 2466-2476https://doi.org/10.1158/1078-0432.CCR-19-3579
- The role of APC in WNT pathway activation in serrated neoplasia.Mod Pathol Off J U S Can Acad Pathol Inc. 2018; 31: 495-504https://doi.org/10.1038/modpathol.2017.150
- RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.Oncotarget. 2016; 7: 70589-70600https://doi.org/10.18632/oncotarget.12130
- Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification.Gut. 2020; 69: 1092-1103https://doi.org/10.1136/gutjnl-2019-319126
Hallmark_WNT_beta_catenin_signaling n.d. https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_WNT_BETA_CATENIN_SIGNALING (accessed January 31, 2021).
- A phase 2 study of dabrafenib and trametinib in combination with PDR001 in patients with BRAFV600E metastatic colorectal cancer.clinicaltrials.gov, 2018
- Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X).clinicaltrials.gov, 2019
- Phase I/II trial of encorafenib, binimetinib, and nivolumab in microsatellite stable BRAF V600E metastatic colorectal cancer.clinicaltrials.gov, 2020
- Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma.J Pathol. 2016; 239: 133-138https://doi.org/10.1002/path.4709
- Wnt addiction of genetically defined cancers reversed by PORCN inhibition.Oncogene. 2016; 35: 2197-2207https://doi.org/10.1038/onc.2015.280
- Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function.Nature. 2016; 529: 97-100https://doi.org/10.1038/nature16466
- A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant KRAS wild-type metastatic colorectal cancer harboring Wnt pathway mutations.clinicaltrials.gov, 2017
- Wnt/β-Catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer.Mol Canc Therapeut. 2018; 17: 806-813https://doi.org/10.1158/1535-7163.MCT-17-0561
Article info
Publication history
Published online: June 11, 2021
Accepted:
April 24,
2021
Received in revised form:
April 19,
2021
Received:
February 24,
2021
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
